Targets › LPIN1
1 program from 1 company in 1 trial: 1 Phase 2; Respiratory; next expected readout Nov 2026.
Acts as a magnesium-dependent phosphatidate phosphatase enzyme which catalyzes the conversion of phosphatidic acid to diacylglycerol during triglyceride, phosphatidylcholine and phosphatidylethanolamine biosynthesis and therefore controls the metabolism of fatty acids at different levels. Is involved in adipocyte differentiation (By similarity). (UniProt, Q14693)
Open in Phaseline: the race on LPIN1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Calluna Pharma | CAL101 LPIN1 inhibitor | LPIN1 | Phase 2 | Idiopathic Pulmonary Fibrosis | Nov 2026 |
Idiopathic Pulmonary Fibrosis (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.